Clinical

Dataset Information

0

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors


ABSTRACT: Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

DISEASE(S): Solid Tumor,Non-small Cell Lung Cancer,Colorectal Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung

PROVIDER: 2378840 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-08-26 | GSE82161 | GEO
2015-11-11 | GSE66999 | GEO
2009-04-01 | GSE12062 | GEO
| EGAS00001006173 | EGA
| EGAD00001006631 | EGA
2024-07-11 | GSE271668 | GEO
| 2533271 | ecrin-mdr-crc
| 2518758 | ecrin-mdr-crc
| 2318715 | ecrin-mdr-crc
| 2520710 | ecrin-mdr-crc